Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Research & Development

Groundbreaking research suggests plastic waste could be used to make anti-cancer drugs

A discovery made by the University of St Andrews has revealed a way to turn ordinary household plastic waste into the building block for anti-cancer treatments
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Subscribe now